Related Experiment Video
Updated: Nov 10, 2025
04:30
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
25.9K
In older adults without CVD, treating 100 persons with statins for 2.5 y prevents 1 MACE
1VA Bedford Healthcare System, Bedford, Massachusetts, USA (L.S.L.).
Annals of Internal Medicine
|April 5, 2021
Insights
Statins significantly reduce cardiovascular events in adults aged 50-75 for primary prevention. The time to benefit varies, with substantial risk reduction observed within 2 years for most individuals.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Preventive Health
Background:
- Primary prevention of cardiovascular events (CVEs) is crucial in adults.
- Statins are widely used for CVE risk reduction.
- Understanding the time to benefit for statins is essential for clinical decision-making.
Purpose of the Study:
- To evaluate the time to benefit of statins for primary prevention of CVEs.
- To analyze the temporal relationship between statin initiation and risk reduction.
- To inform guidelines on statin therapy for primary prevention.
Main Methods:
- Meta-analysis of randomized controlled trials (RCTs) involving statins for primary prevention.
- Inclusion of adults aged 50 to 75 years.
- Assessment of time-dependent effects on CVE incidence.
Main Results:
- Statins demonstrated a significant reduction in CVEs for primary prevention.
- The time to benefit was relatively short, with substantial risk reduction observed within 2 years.
- Absolute risk reduction varied based on individual risk profiles.
Conclusions:
- Statin therapy provides timely benefits for primary prevention of cardiovascular events in adults aged 50-75.
- The findings support the use of statins in appropriate populations for early risk reduction.
- Further research may refine personalized benefit timelines based on risk stratification.
Abstract
Source Citation:
Yourman LC, Cenzer IS, Boscardin WJ, et al. Evaluation of time to benefit of statins for the primary prevention of cardiovascular events in adults aged 50 to 75 years: a meta-analysis. JAMA Intern Med. 2021;181:179-85. 33196766.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.1K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.1K
01:26Atherosclerosis III: Management
98
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
98
01:27Coronary Artery Disease V: Interprofessional Care
107
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
107
01:26Coronary Artery Disease IV: Preventive Measures
448
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
448
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
66
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
66
01:26Angina IV: Management
106
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
106